Results 301 to 308 of about 58,205 (308)

Abstract 4620: Wild-type IDH1: A molecular target in IDH1 mutant cancers

Cancer Research, 2014
Abstract Neomorphic mutations targeting R132 of the TCA cycle enzyme, IDH1, have been identified in multiple cancer types and lead to a build up of (R)-2-hydroxyglutarate ((R)-2HG). Several mechanisms have been proposed to account for mutant-IDH1-mediated transformation: due to its structure similarity with alpha-ketoglutarate (α-KG), (R)
Julie A. Wickenden, Paul Russell, Amy Smith, Tom Henley, Jane Elliott, Dan Gitterman, Mark Stockdale, Christine Schofield, Chris Torrance, Jonathan D. Moore   +9 more
openaire   +1 more source

[IDH1, IDH2].

Nihon rinsho. Japanese journal of clinical medicine, 2019
Hiromichi, Suzuki, Kosuke, Aoki, Fumiharu, Ohka, Atsushi, Natsume   +3 more
openaire   +1 more source

IDH1

2018
openaire   +1 more source

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

The Lancet Oncology, 2020
Lorenzo, Gervaso, Stefania, Pellicori, Nicola, Fazio   +2 more
openaire   +2 more sources

IDH1 (Isocitrate Dehydrogenase 1)

2016
Ivi Juliana Bristot, Fernanda Stapenhorst França, Fábio Klamt   +2 more
openaire   +1 more source

Monoclonal Antibody RcMab-1 Against IDH1

Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 2013
openaire   +2 more sources

IDH1 and IDH2 Mutations

2016
openaire   +1 more source

Ivosidenib effective in IDH1-mutant AML

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources